Michael J Willis

Address:

11328 Wagon Pl, El Paso, TX 79934

Phone:

(915)9299080

VIN:

5XXGN4A7XCG049325

Make:

KIA

Model:

OPTIMA

Year:

2012

US Patent:

6426335, Jul 30, 2002

Filed:

Mar 13, 2000

Appl. No.:

09/254968

Inventors:

Nebojsa Janjic - Boulder CO
Larry Gold - Boulder CO
Paul Schmidt - Niwot CO
Chandra Vargeese - Thornton CO
Michael Willis - Louisville CO

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

A61K 3170

US Classification:

514 44, 536 231

Abstract:

This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

US Patent:

6482594, Nov 19, 2002

Filed:

Jun 14, 2001

Appl. No.:

09/882246

Inventors:

Larry Gold - Boulder CO
Michael Willis - Louisville CO
Tad Koch - Boulder CO
Steven Ringquist - Lyons CO
Kirk Jensen - Boulder CO
Brent Atkinson - Boulder CO

Assignee:

SomaLogic, Inc. - Boulder CO

International Classification:

C12Q 168

US Classification:

435 6, 435 912, 536 231, 536 2433, 536 254

Abstract:

Methods to obtain nucleic acid ligands that photocrosslink to target molecules associated with a disease state are provided. The methods presented are variations on the photoSELEX methods for obtaining nucleic acid ligands. In one method, a candidate mixture of photocrosslinkable nucleic acids is contacted with a biological substance obtained from a source associated with a disease state suspected of containing a target molecule to form nucleic acid-target molecule complexes, the complexes are irradiated to form crosslinked complexes, the photocrosslinked complexes are partitioned from the remainder of the candidate mixture; and the nucleic acid ligands that photocrosslink to molecule are retained. These nucleic acids are then contacted with a second biological substance of the same type as the first, but obtained from a source not associated with a disease state. This removes nucleic acids with affinity to molecules that are not associated with the disease state.

US Patent:

6962784, Nov 8, 2005

Filed:

Jul 25, 2002

Appl. No.:

10/205009

Inventors:

Nebojsa Janjic - Boulder CO, US
Larry Gold - Boulder CO, US
Paul Schmidt - Niwot CO, US
Chandra Vargeese - Thornton CO, US
Michael Willis - Louisville CO, US

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C12Q001/68
C07H021/04
C12P016/34

US Classification:

435 6, 435 912, 536 231, 536 243, 536 2331, 536 254, 424 173, 424 121

Abstract:

This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

US Patent:

8096625, Jan 17, 2012

Filed:

May 19, 2008

Appl. No.:

12/123313

Inventors:

Michael G. Willis - Colorado Springs CO, US

International Classification:

A47B 3/00

US Classification:

312122, 312126, 3123483, 312194

Abstract:

A project management desk having a transparent working surface supported by spaced apart legs and below which is disposed a sliding tray having a plurality of side by side document compartments, the contents of which are visible through the working surface.

US Patent:

20040132067, Jul 8, 2004

Filed:

Oct 8, 2003

Appl. No.:

10/681822

Inventors:

Larry Gold - Boulder CO, US
Michael Willis - Louisville CO, US
Tad Koch - Boulder CO, US
Steven Ringquist - Lvons CO, US
Kirk Jensen - Boulder CO, US
Brent Atkinson - Winterthur, CH

Assignee:

SOMALOGIC, INC.

International Classification:

C12Q001/68
C07H021/04
C12P019/34

US Classification:

435/006000, 435/091200, 536/023100

Abstract:

A method for identifying nucleic acid ligands to target molecules using the SELEX procedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partitioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.

US Patent:

20040192632, Sep 30, 2004

Filed:

Apr 26, 2004

Appl. No.:

10/832941

Inventors:

Nebojsa Janjic - Boulder CO, US
Larry Gold - Boulder CO, US
Paul Schmidt - Niwot CO, US
Chandra Vargeese - Thorton CO, US
Michael Willis - Louisville CO, US

Assignee:

Gilead Sciences, Inc.

International Classification:

A61K048/00

US Classification:

514/044000, 525/054200

Abstract:

This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

US Patent:

20080005003, Jan 3, 2008

Filed:

Mar 7, 2007

Appl. No.:

11/683347

Inventors:

Michael Willis - Colorado Springs CO, US

International Classification:

G06Q 40/00

US Classification:

70503600R

Abstract:

A method of managing an open-ended investment fund of funds traded on a public exchange includes selecting the funds for the investment fund to include the asset classes of bonds and capital, and the asset sectors of real estate, raw materials, and energy. The asset classes and asset sectors are also weighted substantially equally to form the investment fund. Rebalancing of the selected asset classes and asset sectors occurs over time to maintain the equal weighting of the asset classes and asset sectors.

US Patent:

57631778, Jun 9, 1998

Filed:

Mar 8, 1996

Appl. No.:

8/612895

Inventors:

Larry Gold - Boulder CO
Michael Willis - Louisville CO
Tad Koch - Boulder CO
Steven Ringquist - Lyons CO
Kirk Jensen - Boulder CO
Brent Atkinson - Boulder CO

Assignee:

NeXstar Pharmaceuticals, Inc. - Boulder CO

International Classification:

C12Q 168
C12P 1934
C07H 2102
C07H 2104

US Classification:

435 6

Abstract:

A method for identifying nucleic acid ligands to target molecules using the SELEX pocedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.